<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152239</url>
  </required_header>
  <id_info>
    <org_study_id>MSE SB study</org_study_id>
    <nct_id>NCT04152239</nct_id>
  </id_info>
  <brief_title>Utility of Motorized Spiral Enteroscopy for Suspected Small Bowel Pathology</brief_title>
  <acronym>MSESB</acronym>
  <official_title>Prospective Evaluation of the Utility of Motorized Spiral Enteroscopy in Patients With Suspected Small Bowel Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis and treatment of small bowel pathologies remain challenging due to the long length
      of the small bowel. Obscure gastrointestinal (GI) bleeding with negative upper and lower GI
      workup, suspected inflammatory bowel disease, and suspected tumors of the small bowel often
      require small bowel investigation.

      While video capsule endoscopy (VCE) and computed tomography (CT) enteroclysis (CTE) are often
      the initial diagnostic modalities for suspected small bowel pathologies and can provide
      structural information of the small bowel mucosa, biopsy or therapy for the detected
      pathology could not be performed with VCE or CTE. In patients who require biopsy or therapy
      of the detected small bowel pathology, deep enteroscopy would be the procedure of choice in
      modern clinical practice before subjecting patient to surgery.

      Diagnostic and therapeutic deep enteroscopy can be performed by balloon overtube assisted
      enteroscopy (eg, double balloon enteroscopy (DBE), single balloon enteroscopy (SBE) or spiral
      overtube assisted enteroscopy (SE). Despite the difference in equipment design of DBE, SBE,
      and SE, the concepts for small bowel intubation by pleating the intestine over the endoscope
      are the same behind these techniques. Depending on the location of the small bowel pathology
      reported by VCE or CTE, antegrade (oral route), retrograde (anal route), or combined
      antegrade and retrograde deep enteroscopy for total enteroscopy can be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis and treatment of small bowel pathologies remain challenging due to the long length
      of the small bowel. Obscure gastrointestinal (GI) bleeding with negative upper and lower GI
      workup, suspected inflammatory bowel disease, and suspected tumors of the small bowel often
      require investigations of the small bowel.

      While video capsule endoscopy (VCE) and computed tomography (CT) enteroclysis (CTE) are often
      the initial diagnostic modalities for suspected small bowel pathologies and can provide
      structural information of the small bowel mucosa, biopsy or therapy for the detected
      pathology could not be performed with VCE or CTE. In patients who require biopsy or therapy
      of the detected small bowel pathology between the ligament of Treitz and ileocecal valve,
      deep enteroscopy would be the procedure of choice in modern clinical practice before
      subjecting patient to surgery.

      Diagnostic and therapeutic deep enteroscopy can be performed by balloon overtube assisted
      enteroscopy (eg, double balloon enteroscopy (DBE), single balloon enteroscopy (SBE) or spiral
      overtube assisted enteroscopy (SE)). Despite the difference in equipment design of DBE, SBE,
      and SE, the concept for small bowel intubation by pleating the intestine over the endoscope
      is the same behind these techniques. Depending on the location of the small bowel pathology
      reported by VCE or CTE, antegrade (oral route), retrograde (anal route), or combined
      antegrade and retrograde deep enteroscopy for total enteroscopy can be performed. In patients
      with suitable anatomy, total enteroscopy by antegrade approach alone may be achieved.

      DBE was introduced in 2001 and has been the most studied form of modern deep enteroscopy. In
      a recent systematic review of 12823 procedures, the overall diagnostic yield was found to be
      68.1%. The pooled total enteroscopy rate was 44% by the combined anterograde and retrograde
      approach or antegrade-only approach. The pooled minor and major adverse event (eg,
      perforation, bleeding, pancreatitis, aspiration pneumonia) rates were 9.1% and 0.72%,
      respectively. Despite its clinical utility, long procedure time (usually more than 1 to 1.5
      hour) and the need for 2-operators are often regarded as drawbacks of DBE. SE was
      subsequently designed to address this issue with the use of a spiral overtube by manual
      rotation for efficient small bowel intubation. When compared to balloon overtube assisted
      enteroscopy, the main advantage of SE is the relative reduction in procedure time. However,
      the total enteroscopy rate of SE is lower, mainly due to difficult overtube and endoscope
      passage in retrograde procedures. Adverse events with SE (eg, minor mucosal tears,
      perforation, etc) have been reported to be 0.3%. Because both DBE and SE have its own
      shortcomings, the need to further improve the current technology of deep enteroscopy has
      always been present.

      Recently, a motorized spiral enteroscope (MSE) (Olympus Medical, Tokyo, Japan) has become
      available and has the potential to address the shortcomings of the DBE and SE. MSE is an
      enteroscope equipped with a short spiral overtube propelled by a endoscopist-controlled motor
      contained in the handle of the endoscope. The endoscopist controls the left-right and up-down
      movements by the usual manuvers while the forward or backward advancement of the enteroscope
      would be contolled by a foot pedal that activates the spiral overtube rotation. The basic
      principle of small bowel pleating over the endoscope by the use of an overtube to achieve
      deep small bowel intubation is similar to that of DBE and SE. During the procedure, a visual
      force gauge allows the operator to monitor the direction of overtube rotation and the
      resistance applied to the spiral overtube in the small bowel. If excessive rotational
      resistance is detected, the motor would be stopped automatically to avoid mucosal trauma in
      the intestine. The initial experience of MSE in patients with small bowel pathology and
      colonic pathology appears promising with a diagnostic yield of 76 - 88%, therapeutic yield of
      76%, a total enteroscopy rate of 70% (combined antegrade and retrograde approaches or
      antegrade alone approach) and shorter procedure time (&lt; 40 minutes). Based on data from three
      studies including a total of 110 MSE procedures, no serious adverse event such as perforation
      has been reported. The overall adverse event rate including erosion, mucosal tear, hematoma,
      transient swallowing discomfort, etc, was reported to be 20% in a study with 30 patients.
      Despite its potential to improve the clinical management of patients with small bowel
      disorders, current data on the diagnostic and therapeutic utility of MSE is from expert
      European centers and remains limited. Investigators therefore propose this study to evaluate
      the utility of the MSE in patients with suspected small bowel pathology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Diagnostic yield: defined as successful identification of the suspected pathology based on clinical presentation, pre-MSE small bowel imaging or capsule endoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>peri-procedure</time_frame>
    <description>- defined as successful advancement of enteroscope beyond the ligament of Treitz for antegrade procedures, or successful advancement of enteroscope proximal to the ileocecal valve for retrograde procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic yield</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Therapeutic yield: defined as successful endoscopic interventions such as treatment for GI bleeding, polypectomy, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion time</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Insertion time: defined as time to the maximal depth of insertion in small bowel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal depth of insertion in small bowel</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Maximal depth of insertion in small bowel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of total enteroscopy</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Rate of total enteroscopy achieved by antegrade approach alone or combined antegrade and retrograde approaches if total enteroscopy is indicated by findings on pre-MSE small bowel imaging or capsule endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to procedure</measure>
    <time_frame>peri-procedure</time_frame>
    <description>Adverse events related to procedure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Small Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Study group includes consecutive patients with suspected small bowel pathology based on clinical presentation, small bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic enteroscopy. Patients fulfilling the inclusion criteria and without exclusion criteria would undergo MSE per study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Motorized spiral enteroscopy (MSE)</intervention_name>
    <description>Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients with suspected small bowel pathology indicated for deep enteroscopy
        for diagnostic +/- therapeutic procedure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years

          -  Patients with suspected small bowel pathology based on clinical presentation, small
             bowel imaging or capsule endoscopy indicated for diagnostic and/or therapeutic
             enteroscopy

          -  Written informed consent available

        Exclusion Criteria:

          -  Contraindications for endoscopy due to comorbidities

          -  Unable to provide written informed consent

          -  Patients with known severe GI tract inflammation, intestinal obstruction,
             gastroesophageal varices that preclude a safe enteroscopy procedure

          -  Coagulopathy or thrombocytopenia that cannot be corrected by blood product transfusion

          -  Pregnant patients

          -  Moribund patients from terminal illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Raymond Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Lam, BS</last_name>
    <phone>852-3505-3509</phone>
    <email>thomaslam@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Lam, BS</last_name>
      <phone>852-3505-3509</phone>
      <email>thomaslam@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Raymond S Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 2, 2019</study_first_submitted>
  <study_first_submitted_qc>November 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Raymond Shing Yan Tang</investigator_full_name>
    <investigator_title>Clinical Professional Consultant</investigator_title>
  </responsible_party>
  <keyword>enteroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

